185 related articles for article (PubMed ID: 36651232)
1. Effective personalized neoantigen vaccine plus anti-PD-1 in a PD-1 blockade-resistant lung cancer patient.
Gao S; Wang J; Zhu Z; Fang J; Zhao Y; Liu Z; Qin H; Wei Y; Xu H; Dan X; Yang L; Xu Q
Immunotherapy; 2023 Feb; 15(2):57-69. PubMed ID: 36651232
[TBL] [Abstract][Full Text] [Related]
2. Personalized neoantigen vaccine enhances the therapeutic efficacy of bevacizumab and anti-PD-1 antibody in advanced non-small cell lung cancer.
Lin X; Tang S; Guo Y; Tang R; Li Z; Pan X; Chen G; Qiu L; Dong X; Zhang L; Liu X; Cai Z; Xie B
Cancer Immunol Immunother; 2024 Jan; 73(2):26. PubMed ID: 38280084
[TBL] [Abstract][Full Text] [Related]
3. A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer.
Ott PA; Hu-Lieskovan S; Chmielowski B; Govindan R; Naing A; Bhardwaj N; Margolin K; Awad MM; Hellmann MD; Lin JJ; Friedlander T; Bushway ME; Balogh KN; Sciuto TE; Kohler V; Turnbull SJ; Besada R; Curran RR; Trapp B; Scherer J; Poran A; Harjanto D; Barthelme D; Ting YS; Dong JZ; Ware Y; Huang Y; Huang Z; Wanamaker A; Cleary LD; Moles MA; Manson K; Greshock J; Khondker ZS; Fritsch E; Rooney MS; DeMario M; Gaynor RB; Srinivasan L
Cell; 2020 Oct; 183(2):347-362.e24. PubMed ID: 33064988
[TBL] [Abstract][Full Text] [Related]
4. Personalized neoantigen vaccine NEO-PV-01 with chemotherapy and anti-PD-1 as first-line treatment for non-squamous non-small cell lung cancer.
Awad MM; Govindan R; Balogh KN; Spigel DR; Garon EB; Bushway ME; Poran A; Sheen JH; Kohler V; Esaulova E; Srouji J; Ramesh S; Vyasamneni R; Karki B; Sciuto TE; Sethi H; Dong JZ; Moles MA; Manson K; Rooney MS; Khondker ZS; DeMario M; Gaynor RB; Srinivasan L
Cancer Cell; 2022 Sep; 40(9):1010-1026.e11. PubMed ID: 36027916
[TBL] [Abstract][Full Text] [Related]
5. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review.
Kitagawa S; Hakozaki T; Kitadai R; Hosomi Y
Thorac Cancer; 2020 Jul; 11(7):1927-1933. PubMed ID: 32421224
[TBL] [Abstract][Full Text] [Related]
6. Advanced Pancreatic Cancer Patient Benefit From Personalized Neoantigen Nanovaccine Based Immunotherapy: A Case Report.
Shao J; Liu Q; Shen J; Qian X; Yan J; Zhu Y; Qiu X; Lu C; Cen L; Tian M; Du J; Liu B
Front Immunol; 2022; 13():799026. PubMed ID: 35273594
[TBL] [Abstract][Full Text] [Related]
7. Contribution of pre-existing neoantigen-specific T cells to a durable complete response after tumor-pulsed dendritic cell vaccine plus nivolumab therapy in a patient with metastatic salivary duct carcinoma.
Ichimiya S; Fujimura A; Masuda M; Masuda S; Yasumatsu R; Umebayashi M; Tanaka H; Koya N; Nakagawa S; Yew PY; Yoshimura S; Onishi H; Nakamura M; Nakamura Y; Morisaki T
Immunol Invest; 2022 Jul; 51(5):1498-1514. PubMed ID: 34486463
[TBL] [Abstract][Full Text] [Related]
8. Recent advances in neoantigen vaccines for treating non-small cell lung cancer.
Su S; Chen F; Xu M; Liu B; Wang L
Thorac Cancer; 2023 Dec; 14(34):3361-3368. PubMed ID: 37905603
[TBL] [Abstract][Full Text] [Related]
9. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
10. Comparison of personal and shared frameshift neoantigen vaccines in a mouse mammary cancer model.
Peterson M; Murphy SN; Lainson J; Zhang J; Shen L; Diehnelt CW; Johnston SA
BMC Immunol; 2020 May; 21(1):25. PubMed ID: 32370785
[TBL] [Abstract][Full Text] [Related]
11. Personalized neoantigen vaccine prevents postoperative recurrence in hepatocellular carcinoma patients with vascular invasion.
Cai Z; Su X; Qiu L; Li Z; Li X; Dong X; Wei F; Zhou Y; Luo L; Chen G; Chen H; Wang Y; Zeng Y; Liu X
Mol Cancer; 2021 Dec; 20(1):164. PubMed ID: 34903219
[TBL] [Abstract][Full Text] [Related]
12. Cancer neoantigens as potential targets for immunotherapy.
Ma W; Pham B; Li T
Clin Exp Metastasis; 2022 Feb; 39(1):51-60. PubMed ID: 33950415
[TBL] [Abstract][Full Text] [Related]
13. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
[TBL] [Abstract][Full Text] [Related]
14. Identification of Individual Cancer-Specific Somatic Mutations for Neoantigen-Based Immunotherapy of Lung Cancer.
Karasaki T; Nagayama K; Kawashima M; Hiyama N; Murayama T; Kuwano H; Nitadori J; Anraku M; Sato M; Miyai M; Hosoi A; Matsushita H; Kikugawa S; Matoba R; Ohara O; Kakimi K; Nakajima J
J Thorac Oncol; 2016 Mar; 11(3):324-33. PubMed ID: 26752676
[TBL] [Abstract][Full Text] [Related]
15. Advances in personalized neoantigen vaccines for cancer immunotherapy.
Sun C; Xu S
Biosci Trends; 2020 Nov; 14(5):349-353. PubMed ID: 32908077
[TBL] [Abstract][Full Text] [Related]
16. Personalized neoantigen-based immunotherapy for advanced collecting duct carcinoma: case report.
Zeng Y; Zhang W; Li Z; Zheng Y; Wang Y; Chen G; Qiu L; Ke K; Su X; Cai Z; Liu J; Liu X
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439798
[TBL] [Abstract][Full Text] [Related]
17. Preliminary clinical study of personalized neoantigen vaccine therapy for microsatellite stability (MSS)-advanced colorectal cancer.
Yu YJ; Shan N; Li LY; Zhu YS; Lin LM; Mao CC; Hu TT; Xue XY; Su XP; Shen X; Cai ZZ
Cancer Immunol Immunother; 2023 Jul; 72(7):2045-2056. PubMed ID: 36795124
[TBL] [Abstract][Full Text] [Related]
18. Combination TIGIT/PD-1 blockade enhances the efficacy of neoantigen vaccines in a model of pancreatic cancer.
Peng H; Li L; Zuo C; Chen MY; Zhang X; Myers NB; Hogg GD; DeNardo DG; Goedegebuure SP; Hawkins WG; Gillanders WE
Front Immunol; 2022; 13():1039226. PubMed ID: 36569934
[TBL] [Abstract][Full Text] [Related]
19. Late-differentiated effector neoantigen-specific CD8+ T cells are enriched in peripheral blood of non-small cell lung carcinoma patients responding to atezolizumab treatment.
Fehlings M; Jhunjhunwala S; Kowanetz M; O'Gorman WE; Hegde PS; Sumatoh H; Lee BH; Nardin A; Becht E; Flynn S; Ballinger M; Newell EW; Yadav M
J Immunother Cancer; 2019 Sep; 7(1):249. PubMed ID: 31511069
[TBL] [Abstract][Full Text] [Related]
20. Personalized neoantigen vaccines: A new approach to cancer immunotherapy.
Aldous AR; Dong JZ
Bioorg Med Chem; 2018 Jun; 26(10):2842-2849. PubMed ID: 29111369
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
